SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Merger of Acceleron Pharma Inc. with Merck & Co., Inc.
New York, New York--(Newsfile Corp. - October 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:
To: All Persons or Entities who purchased Acceleron Pharma Inc. (NASDAQ: XLRN) ("Acceleron" or "Company") stock prior to September 30, 2021.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Acceleron with Merck & Co., Inc. Under the terms of the merger, Acceleron stockholders will receive $180 in cash for each share of Acceleron common stock owned.
To learn more about the action and your rights, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500. There is no cost or obligation to you.
The Acceleron merger investigation concerns whether the Board of Acceleron has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/98534